UroGen Pharma Ltd. has announced that the U.S. Food and Drug Administration (FDA) cleared the company’s Investigational New Drug application (IND) for UGN-501, a next-generation investigational oncolytic virus.
The IND clearance enables initiation of a planned phase 1 clinical study in patients with non-muscle invasive bladder cancer (NMIBC). The phase 1 study is expected to begin in Q4 2026 and will evaluate the safety, tolerability, and feasibility of intravesical administration of UGN-501.
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, chief medical officer of UroGen.
“UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumour cells while generating an anti-tumour immune response. FDA clearance of the IND allows us to begin evaluating whether the encouraging nonclinical profile of UGN-501 can translate into a safe and meaningful therapeutic approach for patients with NMIBC. We look forward to initiating the phase 1 study and advancing our efforts to develop innovative treatment options for patients with bladder cancer.”
NMIBC continues to present significant clinical challenges, particularly among patients whose disease recurs following standard treatment. Despite available therapies, recurrence rates remain substantial, underscoring the need for novel bladder-sparing therapeutic approaches. UroGen believes UGN-501’s differentiated mechanism of action and local administration strategy may offer a promising new approach for addressing this unmet need.
UGN-501 is designed to selectively replicate within tumour cells, resulting in direct tumour cell destruction and an anti-tumour immune response. The program is supported by nonclinical data demonstrating cytotoxic activity across a broad panel of bladder cancer cell lines representing multiple stages and grades of disease.
While UGN-501 is initially being developed for bladder cancer, the company said it believes UGN-501’s underlying properties may have broader applicability across additional solid tumour indications and intends to evaluate future development opportunities based on emerging clinical and translational data.